Theralase Technologies Inc. V.TLT

Divestiture a Solution?

[Infinity]

I believe if RDW could find a buyer or JV for just the Device division.  Spin off just the device part of the business. Perhaps another company that specialises only in Medical equipment and devices.  This should generate enough cash flow to get us over to BTD and better valuation.  There are two benefits, one is RDW can concentrate on the core business which is ACT and expand into Antivirus which is already in the works.  It will reduce some payroll expenses and offer RDW and Dr. Mandel more time to work on the clinical study part and FDA relationship building to get us to the finish line.  JMO

[Longholder99]

Suggesting the need for a solution brings with it the suggestion that there is a problem???  The compnay has no debt ...i repeat, no debt.  Financing...albeit not to the liking of the armchair quarterbacks who seem to be coming out of the woodwork lately....has been well addressed through small PP's in what appears to be an effort to incrementally keep the lights on while maintaining

[Alamir1111]

Hi Longholder what would be your qualification or field of experience  in  this matter? Financing...albeit not to the liking of the armchair quarterbacks who seem to be coming out of the woodwork lately.

[Alamir1111]

Study II commenced in April 2019 with an estimated completion time of approximately 8 years and an estimated cost of approximately $CAN 100 million. The timing and cost may vary significantly depending on numerous factors; including: number of Clinical Study Sites (" CSSs ") enrolling and treating patients, patient enrollment rates in total and at each CSS, patient compliance

[2b7f6fab]

Infinity I like your idea.  For years I've pointed out that the device division has been a huge money losing venture.  Theralase would not have needed nearly as many PPs.  I understand back in the early years there may have been a desire to keep it going just in case the ACT didn't pan out.  However, with the CR performance we've seen over the past few years

[Alamir1111]

Financing...albeit not to the liking of the armchair quarterbacks who seem to be coming out of the woodwork lately. Net research and development expenses for the Device Division increased to $138,215 from $34,844 for the same period in 2023, a 297% increase. The increase is attributed to development of a new software program for the TLC-2000 Cool Laser Therapy system.